Androgen receptor (AR) overexpression is one of the characteristics of prostate cancer (PC) that progresses to hormone independence. An androgen-independent (AI) derivative, with much higher AR-mRNA and protein levels than the parental LNCaP cell line, whose proliferation was androgen dependent (AD), was used to explore the mechanism of AR overexpression. We found that a suppressor element (ARS), previously identified in mouse AR and located in the 5 0 -untranslated region of human AR gene, malfunctions in AI cells. Transfection of constructs that included ARS element into AD cells reduced the transactivating activities of both AR promoter and a heterologous SV40 promoter. The deletion of ARS resulted in an eightfold increase in AR-promoter activity in AD cells, but had no effect in AI cells. Moreover, the nuclear extracts of AD cells contained proteins that produced a specific, ARS-binding complex, while this complex appeared to have been lost from AI cells. Most importantly, treatment of AI cells with a demethylating agent or histone deacetylase inhibitors restored the lost ARS-binding complex. The restoration of the complex coincided with a reduced expression of AR-mRNA and protein and a reduced rate of AR-gene transcription, determined by nuclear run-on experiment. Thus, epigenetic transcriptional silencing of the suppressor protein(s) may be responsible for AR overexpression in AI cells, and its reversal in hormone-independent PC may normalize AR levels and restore their hormone dependence.
Introduction
Prostate cancer (PC) is the most common type of cancer found in American men, and androgen deprivation is the major current therapy for advanced PC. This treatment exerts its effect on target tissue by either blocking androgen production or preventing binding of androgen to the androgen receptor (AR). The consequence of both is interference with androgenic effects responsible for cancer cell growth stimulation. However, even the highly androgen-dependent cases of PC that are initially responsive to hormone deprivation therapy eventually develop resistance due to selection or adaptation of androgen-independent (AI) clones (Isaacs and Coffey, 1981; Bruchovsky et al., 1990) . For these patients, no therapy has been shown to substantially extend survival and new therapies are urgently needed.
Abnormalities of the AR play a determinant role in the progression of PC (Culig et al., 2002; Debes and Tindall, 2002) . AR gene mutation and amplification of wild-type AR have been suggested as mechanisms of AR overexpression, while cross talk between growth factor receptors and AR signaling pathways and excessive recruitment of AR transcriptional co-activators have been postulated as mechanisms for its aberrant function. The outcome of these abnormalities is the ability of PC cells to make do with no androgen, or with very low levels of androgen, a state associated with the development of hormone-insensitive PC (Grossmann et al., 2001; Zhou et al., 2001; Culig et al., 2002; Debes and Tindall, 2002; McPhaul, 2002) . Consequently, restoration of normal AR expression/function may prove to be an effective mean of treatment in this stage of the disease. This concept is supported by recent observations that downregulation of AR expression by means of AR antisense oligos, or disruption of AR function via direct injection of AR antibody into cells, produced significant inhibition of proliferation of the refractory PC cells, and induced apoptosis (Eder et al., 2000; Zegarra-Moro et al., 2002) .
In addition to the better-recognized mechanisms of AR overexpression, such as gene amplification, which is responsible for some 30% of AR overexpression (Linja et al., 2001) , there is also evidence that AR levels can be overexpressed in advanced PC in the absence of gene amplification (Latil et al., 2001 ), but little is known about the molecular mechanisms that underlie this aberrant regulation. We established and characterized an AI derivative of a prostate carcinoma LNCaP cell line that strongly overexpresses AR (Gao et al., 1999; Wang et al., 2001 ). This AR is functional and it inhibits the expression of the p21 WAF1/CIP1 gene. Loss of p21 expression may promote hormone-independent growth and mediate resistance to apoptosis in response to chemotherapeutic agents (Gao et al., 1999; Wang et al., 2001 ). Since we found no indication of AR gene amplification in either the parental or the AI-LNCaP cells (results no shown), we focused on the possibility that the level of AR expression may be regulated transcriptionally by factor(s) that are differentially expressed in AD and AI cells. Analysis of the ARpromoter region has been described (Buetter, 1994; Mizokami and Chang, 1994; Takane and McPhaul, 1996) , and binding sites for B20 transcription factors have been mapped (Figure 1 ). Among them are positive regulators, such as SP1-binding sites or consensus HLH protein-binding sites, and negative regulators, such as NF1-and NF-kB-binding sites (Supakar et al., 1993 (Supakar et al., , 1995 Chen et al., 1997; Song et al., 1999) . Moreover, two suppressor elements, one at À864 and a second at À447 bp, have been identified in the 5 0 -flanking region of the mouse AR gene (Kumar et al., 1994; Grossmann and Tindall, 1995) . The suppressor element at À864 bp is believed to attenuate transcription by binding different proteins to the sense and the antisense DNA strands (Grossmann and Tindall, 1995) , while the transcription factors responsible for the function of the mouse ARS element located at À447 bp have not been described. These data and published evidence suggesting that AR expression may be transcriptionally regulated in different adult tissues and during aging (Supakar et al., 1993 (Supakar et al., , 1995 led us to hypothesize that the overexpression of AR in advanced PC may also be subject to a transcriptional regulation. Inspection of the human AR promoter and the 5 0 -untranslated region (5 0 -UTR) revealed a cis-element (323-342 nt) that was similar (except for a single GC inversion) to that located at À447 bp. Using AI-LNCaP cells that strongly overexpress AR, we tested the functionality of this element and its contribution to the regulation of AR expression. We report that, in addition to previously described AR overexpression and other properties characteristic of hormone-refractory PC (Gao et al., 1999; Wang et al., 2001) , the AI cells also lost an AR-suppressor-binding protein complex. Combined treatment with a histone deacetylase inhibitor and/or a demethylating agent treatment led to simultaneous re-expression of the suppressor protein(s) and AR-downregulation in AI cells, thus potentially paving the way for new approaches toward the management of advanced PC.
Results

Identification of an AR suppressor element
We hypothesized that overexpression of AR in the AI cell line may be the consequence of a loss of an ARsuppressor complex that binds to the element located in the 5 0 -UTR of AR gene. To test this hypothesis, we Figure 1 Regulatory sequences in human AR promoter and 5 0 -UTR and constructs used in transfection experiments. Top, AR promoter region and 5 0 -UTR (À5778 to 1127 bp) with previously published response elements (Supakar et al., 1993 (Supakar et al., , 1995 Buetter, 1994; Takane and McPhaul, 1996; Chen et al., 1997; Song et al., 1999) and/or identified by Gene-Runner search; pLARS-1, À741 to 910 bp, includes the suppressor element ARS; pLARS-del, same as pLARS but ARS deleted; pLARS-SB, 5 0 -UTR without promoter but with ARS; pLARS-O, ARS, shown as a single element but used as a three-tandem repeat, cloned upstream of an SV40 promoter. All four constructs were linked to a luciferase reporter as described in Materials and methods
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LG Wang et al constructed a series of AR-luciferase reporters with the putative ARS sequence included or deleted (Figure 1 ), and tested their activity in AD and AI cells. The luciferase activity produced by transfecting cells with a control construct (pLARS-1) spanning À746 to þ 1127 bp, and encompassing the core promoter region (À278 to þ 304 bp) (Mizokami and Chang, 1994; Takane and McPhaul, 1996) , was 14-fold greater in AI cells than in AD cells (Figure 2a ). This result suggested that the ARS sequence might be involved in negative regulation of AR expression in AD cells, and that this effect may be lost in AI cells. Using a construct with a deleted ARS sequence (pLARS-del) (Figure 1 ), we tested whether this was the case. We found that transfection of AD cells with pLARS-del produced an B8-fold higher luciferase activity than that produced by pLARS-1 (Figure 2a ). In contrast, in AI cells these two constructs produced similar levels of luciferase activity ( Figure 2a ). To test more directly the effect of ARS on transcription, we carried out run-on experiments (Wang et al., 1994) using nuclei of AI and AD cells transfected with either pLARS-1 or pLARS-del. We found that deletion of the ARS (pLARS-del) increased the transcription rate in AD cells by more than twofold (Figure 2b ), while not affecting transcription rate in the AI cells (Figure 2b ). The impact of ARS deletion on transcription (run-on assay) in AD cells (Figure 2c ) was qualitatively parallel to the effect on luciferase activity (Figure 2a) , further supporting the notion that the ARS sequence functions as a repressor of AR expression in AD cells, and that this repressor activity malfunctions in AI cells. A construct containing only the 5 0 -UTR with the ARS sequence intact, but with no upstream promoter elements (pLARS-SB), produced no luciferase activity in AD cells, but small but detectable activity in AI cells. Several SP1 sites in the 5 0 -UTR are known to be functional in transactivation of the AR gene (Mizokami and Chang, 1994) , and it is possible that the activity of pLARS-SB in AI cells is due to the predominance of Sp1 effect when the ARS function is disabled. A further proof of transcriptional repression by ARS was obtained by subcloning this element (three-tandem repeats) upstream of a heterologous promoter (SV40) in a luciferase reporter system (see Materials and methods). Insertion of ARS into the pGL3 plasmid produced an B80% inhibition of luciferase activity in AD cells, but only 40% inhibition in AI cells. The Figure 2 The inhibitory effect of ARS on endogenous (AR) and heterologous (SV40) promoter in AD cells is lost in AI cells. (a) Luciferase activity of AD and AI cells 48 h after transfection with 1 mg DNA per dish of the indicated plasmids and 0.5 mg of bgalactosidase DNA. Luciferase activity normalized to b-galactosidase activity. (b) Nuclear run-on experiment of AD and AI cells transfected with 1 mg DNA of pLARS-1 or pLARS-del. Nuclei were prepared 48 h after transfection as previously described (Wang et al., 1994) . Indicated amounts of pGL3, pLARS-1, and GAPDH-DNA were immobilized on the nylon membrane and hybridized with an equal amount of newly transcribed [ 32 P]-UTPlabeled RNA. The hybridization signals were detected by exposure of the membrane to X-ray film. (c) Dot density was measured using an Imaging Densitometer Model GS-720 and the results are plotted. (d) pGL3-C containing SV40 promoter and luciferase reporter, or the same plasmid with three tandem repeats of wtARS or mutant-1ARS (see Materials and methods) inserted upstream of the promoter, was used to transfect AD and AI cells (1 mg DNA per 6-mm dish). Luciferase activity was measured 48 h after transfection and normalized as in (a). *Po0.05; **Po0.01 inhibition of luciferase activity in AD cells was only partially reversed when a mutant ARS (see Materials and methods) was inserted upstream of a heterologous promoter ( Figure 2d ). The partial inhibition observed in AI cells, and the lack of complete reversal of the effect through mutation of the ARS, may be due to the fact that tandem repeats of ARS, which were used in this experiment to maximize the effect of ARS, may have created new binding sites for additional transcription factors. Overall, our data indicate that ARS functions as a suppressor element of AR transcription in AD cells and that its activity is to a large degree disabled in AI cells.
Differential binding of AD and AI cell-nuclear proteins to wtARS
The loss of ARS function in AI cells might be due to the loss of, or change in post-translational modification, of ARS-binding nuclear factor(s). To examine this possibility, nuclear extracts of AD and AI cells were tested for binding activity in an electrophoretic mobility gel shift assay (EMSA). The wtARS double-stranded oligonucleotide 5 0 -ACCCCGCCTCCCCCCACCCT-3 0 corresponding to the sequence between þ 323 and þ 342 bp ( Figure 1 ) and the three ARS mutants (mARS-1, -2, and -3) generated by replacing with AA or TT of two pairs of nucleotides in the binding core of the mouse wtARS sequence were used for EMSA (Kumar et al., 1994) (for details, see Materials and methods). A distinct binding complex was formed when nuclear extracts of AD cells were incubated with the wtARS probe ( Figure 3a ). Under the same experimental conditions, only a barely detectable complex of similar mobility was formed when the nuclear proteins from AI cells were reacted with the same ARS probe ( Figure 3a) . Similarly, the nuclear extract of advanced metastatic prostate carcinoma cells (P918) from a hormonerefractory patient that expressed a high level of AR (results not shown) formed a very weak ARS-binding complex ( Figure 3a) . A more than Â 50 excess of unlabeled wtARS was required to compete fully with the radioactive complex formation (Figure 3b ), suggesting a high-affinity interaction. The ARS-protein complex formed by nuclear extracts of AD cells was specific for double-stranded DNA, since neither sense nor antisense single-stranded ARS-DNA competed for this binding even at Â 100 fold excess (results not shown).
Of the three ARS-mutants (see Materials and methods), each of which had four base mutations, mARS-1 neither competed for wtARS-complex formation ( Figure 3c ) nor bound nuclear proteins derived from AD or AI cells (Figure 3a ), mARS-2 produced four, and mARS-3 two very weak shifted bands, regardless of the source (AD or AI cells) of the nuclear extracts (results not shown). These results indicate that the gel shift produced by wtARS is sequence specific.
To resolve the protein components of the ARSbinding complex, we performed Southwestern blot analysis. PAGE-separated proteins were transferred to a nitrocellulose membrane and blotted with [ 32 P]-labeled wtARS in the presence of 10 mg of unlabeled, mutated (mARS-1) oligo, or [ 32 P]-mARS-1 or wt-Sp1 sequence from human AR promoter (Takane and McPhaul, 1996) , or from human PSA promoter (Wang et al., 1997) . The wtARS probe bound to multiple proteins ( Figure 3d) ; two of the proteins, 51 and 29 kDa, detected by the wtARS sequence, were much more prominent in the extracts of AD cells, suggesting that they may be part of the suppressor complex. The mutated ARS or the wt-Sp1 sequence from the PSA promoter, which is known to be not functional, showed no binding, or very weak binding to the same nuclear extracts. The SP1 sequence from the human AR promoter, known to be important in transactivation of the AR gene, bound to several proteins, but the mobility pattern of these proteins was different from that obtained with the wtARS sequence, and similar in extracts of AD and AI cells. Moreover, in gel shift analysis, antibodies to SP1 did not produce a super-shift of the complex (results not shown). Overall, these results show a unique pattern of ARS-binding proteins in AD cells and suggest the possibility that loss of some of these proteins in AI cells may contribute to the loss of regulation of AR expression.
Restoration of ARS-binding complex and its effect on AR level in AI cells
Recent studies indicate a major role for epigenetic silencing of gene expression, including many genes linked to tumor progression. We postulated that a similar mechanism might be responsible for the loss of ARS-binding proteins and AR overexpression in AI cells. We first tested the effect of treatment of AI cells with a demethylating agent, 5-azacytidine. Results in Figure 4a , right panel, show that nuclear extracts of AI cells treated with 5-Aza for 7 days formed a complex with wtARS that had a similar migration pattern as that of AD cells. Also, since histone acetylation/deacetylation is emerging as an important regulatory mechanism of gene expression (Loidl, 1994; Sowa et al., 1997; Turner, 1998) , we examined whether it had a role in loss of binding activity in AI cells. Nuclear extracts of AI cells treated with trichostatin A (TSA, 0.1 and 0.2 mM), or sodium butyrate (200 mM) for 24 h, bound the labeled wtARS with much greater intensity than extracts of untreated cells (Figure 4a and b), and treatment with TSA and 5-Aza produced a somewhat more complete restoration of the complex (Figure 4a ). To gain additional insight into the nature of the TSA-induced ARS-binding complex, we compared, using Southwestern analysis, the binding of the ARS sequence to nuclear proteins of untreated AD and AI cells, and AI cells after TSA treatment (Figure 4c ). This analysis showed that TSA treatment restored two bands with molecular weights similar to those shown previously to be present in AD cells, but missing from AI cells (Figure 3e ). An additional band not previously seen was also induced by TSA treatment (Figure 4c ).
Until the ARS-binding proteins from AD cells and TSA-treated AI-cells are isolated, sequenced, and compared, it is impossible to decisively conclude that TSA (or 5 0 -Aza) treatment of AI cells indeed restores the missing suppressor protein complex. We argued that this conclusion can be made more plausible even without the final identification of the proteins if we can show that TSA effect and downregulation of AR expression can be functionally linked. To do that, AI cells were treated with increasing concentrations (0.05-0.4 mM) of TSA for 24 h and compared to untreated cells by Western blots for AR protein, Northern blot analysis for AR-RNA and run-on assay for the rate of AR transcription. We found that treatment of AI cells with TSA affected the AR expression in a dose-dependent manner. A concentration of 0.2 mM TSA produced a strong (B70%) reduction in AR protein and mRNA (Figure 5a and b) and a similar reduction in the rate of AR-gene transcription (Figure 5c ). These data suggest that restoration of the ARS-binding complex is linked to a reduction in AR level. , and wt-ARSp1, respectively, in the presence of 1 mg/ml of appropriate oligo competitor as described in the Materials and methods, and exposed to X-ray film at À801C
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Discussion
We describe here what appears to be a novel mechanism of regulation of AR receptor expression in PC cells. It is well established that AR expression in advanced PC is deregulated (Ruizeveld de Winter, 1994; Ruizeveld de Winter et al., 1994; Hobisch et al., 1995; Taplin et al., 1995) and several mechanisms responsible for the deregulation have been described (Grossmann et al., 2001; Zhou et al., 2001; Culig et al., 2002; Debes and Tindall, 2002; McPhaul, 2002) . Most studies in which RT-PCR was used to measure AR-mRNA levels have shown that 100% of advanced, hormone-independent PCs had substantially (2-40 fold) elevated levels of ARmRNA as compared to AD-PC, yet only 30% of those had AR-gene amplification (Latil et al., 2001; Linja et al., 2001) . This suggests that, in the majority of PCs, AR overexpression may be the result of the loss of transcriptional regulation. This conclusion is supported by the evidence showing that in normal adult tissues expressing AR, and even more so during aging, the level of AR fluctuates widely (Supakar et al., 1993 (Supakar et al., , 1995 Banerjee et al., 2001) .
To gain molecular insight into the mechanism that might be responsible for AR deregulation in advanced PC, we developed, by chronically depriving AD-LNCaP cells of androgen, an AI-prostate carcinoma cell line (Gao et al., 1999 ) that overexpressed AR and had other characteristics of advanced hormone-refractory PC (Wang et al., 2001) . AR-mRNA overexpression was previously shown to be the result of acute and chronic withdrawal of androgen in AR-positive tissues in vivo, and in LNCaP cells (Gregory et al., 1998; Culig et al., 1999; Kumar et al., 2002) . The AI-LNCaP cells we have derived do not express endogenous PSA, due most likely to gene hypermethylation, but can transactivate a transfected PSA promoter-reporter construct (Wang et al., 2001) . The lack of PSA expression is found in some patients with advanced disease in which serum PSA levels do not reflect tumor burden (Leo et al., 1991) . Also, it has been shown after a combined androgen blockade, AR expression is preferentially seen in high-grade, high-stage tumors (de Vere White et al., 1997) and a decrease, or sometimes a complete loss, of PSA expression has also been linked to higher histological grades and more undifferentiated phenotypes (Partin et al., 1990; Petros and Andriole, 1993) . Thus, our AI-LNCaP cells model a subset of advanced PC cases characterized by both AR overexpression and PSA downregulation.
The AR-gene promoter is complex with a long (1.1 kb) 5 0 -UTR. The 5 0 -UTR has been implicated in control of mRNA transcription, translation, and processing (Faber et al., 1991) , and several cis-acting elements have been shown to positively regulate AR expression (Mizokami and Chang, 1994; Hobisch et al., 0 -Aza for 7 days, or with both (7 days 5 0 -Aza, last 24 h TSA) (a), or treated for 24 h with sodium butyrate or TSA (b), were reacted with 32 P-labeled wt-ARS and separated on a native PAGE. The binding complexes were visualized by X-ray film. (c) Comparison of the ARS-nuclear proteins from AD, AI, and AI cells treated with TSA by Southwestern analysis: nuclear extracts of untreated AD and AI cells or AI cells treated with TSA for 24 h (50 mg each) were subjected to SDS-PAGE, and electro-transferred to nitrocellulose membrane. The membrane was hybridized with [ 32 P]-labeled oligos of wt-ARS in the presence of 1 mg/ml of unlabeled mARS-1, as described in Materials and methods, and exposed to X-ray film at À801C
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LG Wang et al 1995; Takane and McPhaul, 1996) . However, based on the identification of a suppressor element in the 5 0 -UTR of mouse AR gene (Grossmann and Tindall, 1995) , and our preliminary data, we hypothesized that AR overexpression in AI-LNCaP cells is caused by the loss of transcriptional suppression. Our results provide credence to this hypothesis. First, we identified an element in the human AR-5 0 -UTR that, with the exception of a single GC inversion, is similar to the mouse suppressor element (Kumar et al., 1994) . This element belongs to the family of GC boxes that usually bind Sp/KLF family of zinc-finger proteins, which includes a number of transcriptional repressors (Bouwman and Philipsen, 2002) . We showed that a DNA fragment that contained the core and upstream sequences (À741 nt) of the AR promoter (Figure 1) , and the 5 0 -UTR that included the ARS (323-342 nt), has suppressor activity because when subcloned in front of luciferase reporter (pLARS-1), and transfected into AI cells, it produced high (55 Â 10 5 units/mg) luciferase activity, which was reduced by B93% in AD cells (Figure 2a) . The rate of AR-promoter/luciferase gene transcription measured by nuclear run-on assays of cells transfected with pLARS-1 was also much higher in AI cells, consistent with loss of ARS-mediated repression. Indeed, deletion of ARS produced an B8-fold higher level of AR promoter activity in AD cells, while not affecting the activity in AI cells (Figure 2a) . Moreover, this element suppressed transcription when subcloned in front of SV40 promoter. ARS was found to bind to a nuclear protein(s) present in AD but not AI cells, and this binding was of high affinity and specific, since mutation of several of the base pairs either completely eliminated binding, or produced profiles of shifted bands that were different from the wtARS. More importantly, we showed that treatment of AI cells with either demethylating agent or deacetylase inhibitors restored the pattern of ARS binding typical for AD cells, while inhibiting AR transcription.
Although, our data clearly show that a repressor function is lost in AI cells, the ARS-binding proteins need to be identified before their direct role in regulation of AR transcription can be definitively established and before our work can be extended to clinical material. To test whether the ARS-binding complex contained known transcription factors, we tested several antibodies, including antibodies to SP1 and KLF6, known to bind to GC boxes (Bouwman and Philipsen, 2002) , for their ability to supershift the ARS complex in EMSA assay. Both produced negative results (data not shown). A search for putative transcription factor that may interact with the ARS sequence using Transcription Element Search System (TESS) program (Baxevanis, April 2002) did not produce clear candidates for further study. We have also compared the two cell lines through a large-scale cDNA Affymetric microarray analysis that has identified four repressors, nuclear receptor corepressor 1 (NCOR1), nuclear receptor co-repressor 2 (NCOR2), FBP interacting repressor (FIR), and nucleolar protein Nop30 (NOP), as well as AS3, a mediator of androgen-induced proliferative quiescence (Geck et al., 2000) , as statistically decreased in AI cells (results not shown). Whether these play any role in AR regulation has not yet been established.
Our attempt to resolve proteins bound to the wtARS sequence through Southwestern analysis revealed four high-intensity bands, of which only two (51 kDa and a doublet at B29 kDa) predominated in the nuclear extracts of AD cells. Treatment of AI cells with TSA restored the pattern of bands to resemble that of AD cells (Figure 4c ). An additional, ARS-binding band of higher molecular weight was detected in TSA-treated nuclear extracts of AI cells but its function, if any, has not been examined. Although it is tempting to speculate that one or both (29 and 51 kDa) bands comprise the suppressor complex, because the Southwestern analysis also revealed a number of less intense bands (results not shown), with some more pronounced in extracts of AD cells, it is premature to assign function to these proteins. Moreover, the fact that some proteins (100 and 70 kDa) regardless of their derivation (AD or AI cells) appear to bind efficiently to the ARS probe in Southwestern blot, yet, as shown by AI cells, are incapable of forming shifted complexes with the probe in EMSA, further complicates the conclusions based on Southwestern data analysis. The discrepancy may be due to the difference in assays that compare binding of DNA to protein in solution with binding of a probe to immobilized denatured proteins, and may suggest that in solution these proteins form a complex shielding some from interactions with the DNA.
Is it possible to conclude from our results that the loss and restoration of the repressor proteins (EMSA complex) happens at the level of their expression and not their post-translational modification? Our findings, showing that a demethylating agent, 5-Aza, that works at the DNA level, restores what appears to be a functional ARS complex in AI cells, argue in favor of transcriptional silencing of the repressor protein(s). The ARS-binding complex restoring effect of inhibitors of histone deacetylase (HDAC) activity, alone or in combination with 5-Aza (Cameron et al., 1999) , supports this conclusion, although some direct effects on GC-box-binding proteins affected through interaction with HDAC have been reported (Doetzlhofer et al., 1999) .
Even without a final identification of the protein complex, our data show that a functional repressor element in the 5 0 -UTR of human AR gene, by binding a protein complex, contributes to the normalization of AR level in AD cells. When AD cells are chronically exposed to conditions of hormone deprivation, a situation that may to some extent mimic the hormonal ablation therapy in patients, AR becomes overexpressed due to the loss of transcriptional repressor(s) function. The fact that both the EMSA complex re-expression and AR downregulation are affected through compounds that inhibit HDACs and DNA methylation suggest that the loss of repressor function is epigenetic in nature. While currently this scheme has been established only in a cell model, the identification of the transcription factors, that we are currently pursuing, will help determining if they are also lost during PC progression. Even if the mechanism of silencing of the suppressor proteins, suspected to play a role in the cell model, will not be accurately reproduced in advanced PC, it would be important to identify the proteins and to assess their level and/or their modification in disease progression. If proven relevant to the hormone-refractory PC, restoration of these repressor proteins, and thus downregulation of AR to normal levels, may become a feasible therapeutic goal.
Materials and methods
Reagents
Antibodies against AR and b-actin, as well as secondary antibodies, were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Western blotting detection reagents were from Amersham (Biosciences, Piscataway, NJ, USA). Effectene transfection reagent and luciferase assay kit were acquired from Qiagen (Valencia, CA, USA) and Promega (Madison, WI, USA). Wt-ARS oligonucleotide 5 0 -AC-CCCGCCTCCCCCCACCCT-3 0 corresponding to the sequence between þ 323 and þ 342 nt (Figure 1 ) and all the three mutants (see below) were ordered from Bio-synthesis Inc., (Lewisville, TX, USA). Luciferase vector pSLA3 is a gift from Dr L Blok (Blok et al., 1992) . TSA, sodium butyrate, and other chemicals were purchased from Sigma (St Louis, MO, USA).
Cell culture
LNCaP cell line purchased from the American Type Culture Collection (Rockville, MD, USA) was maintained in RPMI 1640 (GIBCO, Gaithersburg, MD, USA) with 10% heatinactivated bovine serum (FBS). The AI LNCaP derivative of AD-LNCaP cells was maintained in RPMI 1640 medium containing 10% charcoal-stripped, heat-inactivated FBS (CSFBS) (Hyclone Laboratories, Inc., Logan, UT, USA) and 5 mg/ml of insulin as described previously (Gao et al., 1999) . P918 cells were primary cultures of ascitic fluid from peritoneal metastasis of a patient with a hormone-refractory PC.
AR reporter construct
AR luciferase reporter pLARS-1 was constructed by inserting a PCR product of the AR promoter and 5 0 -UTR from À741 to þ 907 of human PC LNCaP cells AR (Figure 1) , into SacI and BglII restriction sites of basic luciferase vector pGL3 (Promega, Madison, WI, USA). To delete the ARS sequence (323-342 nt), for constructing the pLARS-del, two pairs of PCR primers were designed at restriction sites of SacI (5 0 -GTT TAC AGA GCT CTG GAC AAA ATTG-3 0 )-XhoI (AGG CTC GAG AGG AGG AGG ACA AAG GCAG-3 0 ) and XhoI (5 0 -CCT CTC GAG CCT TCC CCC CCT CCC CCG TC-3 0 )-BglII (5 0 -TTC AAA AGA TGC CCA GAT CTT AAA AG-3 0 ). Using these primers, a PCR product was obtained and subcloned into SacI and BglII sites of pGL3 to generate pLARS-del (pLARS-1, but without ARS element). pLARS-SB (B for Bgl II enzyme) was generated by ligation of pGL3 vector with DNA fragment of SamI-BglII obtained by digestion of the AR promoter fragment SacI-BglII from pLARS-1 that covers the AR promoter and 5 0 -UTR sequence from þ 20 to þ 901. All inserted DNA sequences were verified by sequencing.
Construction of ARS-SV40-luciferase reporter plasmid pGL3 control luciferase reporter plasmid (pGL3-C) containing SV40 promoter was purchased from Promega. The plasmid was restricted with MulI and BlgII, and agarose gel purified. Double-stranded oligonucleotides containing three repeats of AR suppressor sequence ARS: CCCGCCTCCCCCCACCC GCCTCCCCCCACCCGCCT CCCCCCA, or its mutant mARS: CCAACCTCCTTCCACCAACCTCCTTCCACCAA CC TCCTTCCA, were inserted into the pGL3-C at restriction sites of MulI and BlgII to generate wild-type pARS-O and its mutant pmARS-O plasmids. The sequence of the insertions was verified.
Transfection and luciferase assay
Exponentially growing AD and AI cells were seeded into 60 mm dishes in medium as described above. After 16 h of incubation, the cells were co-transfected with 1 mg DNA of AR-luciferase reporters, and for internal control 0.5 mg of pSVb-Galactosidase Control Vector (Promega), using Effectene (Qiagen) according to manufacturer's instructions. At 48 h after transfection, the cells were washed, lysed, and used for luciferase and b-galactosidase activity assay with Promega assay kits according to the manufacturer's instructions. The luciferase activities were normalized to b-galactosidase activity and were expressed as units per mg of proteins (Wang et al., 2001) . For testing the effect of ARS on exogenous promoter, the AR-luciferase reporter was substituted with 1 mg of pARSOli or pmARS-Oli and 1 mg of pSV-b-galactosidase.
Western blotting of cellular proteins
AR protein levels were estimated by Western blot analysis as described previously (Wang et al., 1997) . Total cellular proteins were extracted from AI cells 24 h after treatment with the indicated concentrations of TSA. In all, 50 mg cellular protein was separated on a 7.5% SDS-PAGE, electrotransferred to nitrocellulose filters, and immunoblotted with antibodies against AR and b-actin for loading control. Quantitation by densitometry of the X-ray films was done using an Imaging Densitometer Model GS-720 (Bio-Rad Lab. Hercules, CA, USA).
Nuclear run-on assay
Nuclei were prepared as described previously (Wang et al., 1997) . Briefly, exponentially growing AD and AI cells were exposed to indicated concentrations of TSA for 24 h, or transfected with indicated AR constructs pLARS-1 or pLARS-del for 48 h. After washing with cold phosphatebuffered saline (PBS), the cells were resuspended in buffer A (10 mM HEPES, pH 8.0, 50 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, 1.0 mM DTT, 0.5 M sucrose, and 0.1% Triton X-100), and passed several times through 1 ml syringe with 25G5/8 needle, and examined under microscope after addition of Trypan blue. The nuclei were collected by centrifugation at 1000 g, 41C for 10 min, washed once with buffer A, and resuspended in buffer B (40% glycerol, 50 mM Tris-HCl, pH 8.3, 5 mM MgCl 2 , and 0.1 mM EDTA), frozen in dry icealcohol immediately, and stored at À801C. Nuclear transcription assays were carried out at 261C for 10 min as previously described (Wang et al., 1994) in a transcription buffer composed of 3 mM DTT, 1.2 mM MgCl 2 , 80 mM KCl, 300 mM ATP, 150 mM GTP and CTP each, and 200 mCi of [g 32 P]-UTP (3000 Ci/nmol, New England Nuclear Lab, MA, USA).
After 10 min, 15 mg of yeast tRNA was added to the reaction mixture, and RNA was extracted by the guanidinium/phenol method (Chomczynski and Sacchi, 1987) , followed by two ethanol precipitations. The RNA, thus obtained, was quantified by liquid scintillation counting. The indicated amount of DNA probes was boiled for 2 min, chilled immediately in ice bath, and immobilized onto nylon membranes that were dried at 801C for 4 h. After prehybridization of the membranes for 1 h at 651C, equal amount of [ 32 P]-labeled RNA (1-2 Â 10 6 c.p.m.) was added to 3 ml hybridization buffer and the hybridization was processed in a 651C water bath with gentle shaking overnight. After three washes, the membranes were exposed to an X-ray film for 2 days at À801C.
Mobility gel shift assay (EMSA)
Mobility gel shift assay was performed as described previously (Wang et al., 1997) . Briefly, exponentially growing AD and AI cells, or AI cells, treated with indicated concentrations of TSA or sodium butyrate for 24 h in the RPMI 1640 medium containing 10% FBS were harvested, washed once with cold PBS and nuclear proteins extracted in the presence of protease inhibitors, including 1 mg/ml leupeptin, 1 mg/ml pepstain, and 2 mg/ml aprotinin. The proteins were divided into aliquots and stored at À201C until use. Five mg of nuclear protein was reacted for 30 min at room temperature with the [g- 0 , mARS-3: 5 0 -CCTTGCCTAACCCCACCCT-3 0 , or with single-stranded sense and antisense ARS, in a binding buffer composed of 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.5% (v/v) glycerol, and 2.0 mg poly (dI)(dC) in a final volume of 25 ml. The reaction mixtures were then subjected to 8% native low ionic strength PAGE (Wang et al., 1994) . The binding complexes were visualized by exposing the dried gel to X-ray film at À801C overnight.
Southwestern (DNA-protein) blot analysis
Southwestern blot was performed essentially according to a method described by Yang et al. (1994) with modifications. Four aliquots of 50 mg of nuclear extracts from AD and AI cells were subjected to SDS-PAGE, and electro-transferred to a nitrocellulose membrane. The membrane was then cut into four equal parts, and blocked with 5% fat-free dry milk in a binding buffer described in EMSA for 1 h at room temperature. After three washes with the binding buffer, the membranes were hybridized at 41C for 1 h with [ 32 P]-labeled oligos of wt-ARS, mARS-1, wt-PSA-Sp1 (5 0 -CAGG-GCAG GGGCGGAGTCCT) (Riegman et al., 1989; Wang et al., 1997) , and wt-AR-Sp1 (5 0 -CGGCCCGGTGGGGGCGGGAC-3 0 ), respectively, in the presence of 1 mg/ml oligo competitor (mARS-1 for wt-ARS, wt-PSA-Sp1 for mARS-1, mARS-1 for wt-PSA-Sp1, and wt-PSA-Sp1 for wt-AR-Sp1, respectively). After three washes with the binding buffer, the membranes were exposed to X-ray film at À801C. Southwestern analysis of AI cells treated with TSA was performed as described above, except that the cells were treated for 24 h with 0.2 mM TSA.
